SAB Biotherapeutics received FDA Fast Track designation for SAB-142, an immunotherapy targeting Stage 3 type 1 diabetes. This status aims to accelerate the drug's development and review, addressing an unmet medical need. SAB-142 is currently in a Phase 2b trial with data expected in the second half of 2027, potentially offering a new treatment that could delay or prevent disease progression in newly diagnosed patients.
SAB Biotherapeutics' SAB-142 immunotherapy is the subject, with Pluang market data providing context. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 13, 2026 18:43 WIB: Out of 128 priced health-sector US stocks, 76 rose and 46 fell. Notable movers include Incyte Corporation (INCY) at USD 109.38 with a -1.78% change and 100% buy order activity, InMode Ltd (INMD) at USD 14.55 with a +1.75% change and 100% buy order activity, and Abbott Laboratories (ABT) at USD 103.60 with a +1.75% change but 85% sell order activity.
Existing-home sales in the U.S. increased by 1.5% month-over-month in September but declined 2.2% compared to the previous year, according to the National Association of Realtors. Sales rose in the South and West regions but fell in the Northeast and...
Columbus Marketing Experts, a digital marketing agency in Hilliard, Ohio, is expanding its local SEO services across Columbus to help service businesses improve their visibility on Google Search and Google Maps. The expansion aims to enhance local di...
Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Nvidia CEO Jensen Huang has reaffirmed his forecast that global spending on AI infrastructure will grow significantly, reaching between $3 trillion and $4 trillion by 2030. This projection highlights the massive potential and ongoing investment in AI...
